FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1 37 1 4 11 675 2													
1. Name and Address of Reporting Person* WIKLER MATTHEW			2. Issuer Name and Ticker or Trading Symbol Matinas BioPharma Holdings, Inc. [MTNB]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director				
(Last) (First) (Middle) C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH SUITE 302		06/3	3. Date of Earliest Transaction (Month/Day/Year) 06/30/2021					-	Office	er (give title belo	ow)	Other (specify	pelow)
BEDMINSTER,, NJ 07921		4. If A	4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City) (State)	(Zip)		Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned										
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Ye	Execuar) any	Deemed ution Date, it	(Instr. 8		4. Securities Acquire (A) or Disposed of (Instr. 3, 4 and 5)		of (D)	Beneficial Reported	ount of Securities sially Owned Following ed Transaction(s)		\ /	7. Nature of Indirect Beneficial Ownership (Instr. 4)
		(Mon	(Month/Day/Year)		V	Amount	(A) or (D)	Price	(Instr. 3 and 4)				
Common Stock	06/30/2021			A		10,244	A	\$ 0	276,507	1		D	
			enericially o	viied dire	Perso		respor			ction of inf			1474 (9-02)
	Table II	- Deriva	ative Securit	ies Acqui	Personta conta the fo	ons who ained in orm disp	respor this for plays a	m are curren eficiall	not requ itly valid	uired to res	formation spond unle trol numbe	ess	1474 (9-02)
1. Title of Derivative Security (Instr. 3) 2. Conversion Date of Exercise (Month Derivative Security	saction 3A. Deemo	e.g., pr	tive Securit uts, calls, wa 4. Transaction Code (Instr. 8)	ies Acqui arrants, o	Persoconta the formation of the formatio	ons who ained in orm disp	respor this for plays a c , or Beneble secur sable	eficiallrities) 7. Tit Amo Under	not required to the and count of erlying	OMB con 8. Price of	spond unle	of 10. Owners Form of Derivat Security Direct (or Indir	11. Natu of Indire Benefici: Ownersh (Instr. 4)

Reporting Owners

	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
WIKLER MATTHEW C/O MATINAS BIOPHARMA HOLDINGS, INC. 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER,, NJ 07921	X				

Signatures

/s/_Keith A. Kucinski, attorney-in fact for Matthew Wikler			07/01/2021	
	**Signature of Reporting Person		Date	

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) On June 30, 2021, the Reporting Person was issued 10,244 shares of common stock par value \$.0001 per share pursuant to the Issuer's Amended and Restated 2013 Equity Compensation Plan. Such shares vest immediately upon grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.